Estimate the survival (time to progression to hypertension) functions for each treatment group using the Kaplan-Meier approach

A clinical trial is conducted to evaluate the efficacy of a new drug for prevention ofhypertension in patients with pre-hypertension (defined as systolic blood pressure between120–139 mmHg or diastolic blood pressure between 80–89 mmHg). A total of 20 patients arerandomized to receive the new drug or a currently available drug for treatment of high bloodpressure. Participants are followed for up to 12 months, and time to progression tohypertension is measured. The experiences of participants in each arm of the trial are shownbelow.data is on the document. the first oneTo answer the question as to whether or not there is a difference in time to progression, aChi square statistic is computed. The critical value for rejection of the null hypothesis is3.84. The computed Chi square is 0.335.Based on comparing the computed Chi square and the critical Chi square, which of thefollowing is (are) true?A. There is not statistically significant evidence to show that the time to progression isdifferent between groups.B. There is statistically significant evidence to show that the time to progression isdifferent between groups.C. The time to progression is essentially the same for each group.D. a and c.The hazard ratio risk of progression to hypertension is 0.658. Based on this computation,which of the following is (are) true?A. The risk of progression to hypertension is reduced by 34.2% in patients assignedto the new drug as compared to the currently available drug.B. The risk of progression to hypertension is 1.52 times higher in patient’s currentdrug as compared to the new drug.C. The risk of progression to hypertension is 5.12 times higher in patient’s currentdrug as compared to the new drugD. a and b

"Looking for a Similar Assignment? Order now and Get 15% Discount! Use Code "FIRST15"